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Abstract
Exercise capacity (EC) is a critical outcome in chronic obstructive lung disease (chronic obstructive pulmonary
disease (COPD)). It measures the impact of the disease and the effect of specific interventions like pulmonary
rehabilitation (PR). EC determines COPD prognosis and is associated with health-care utilization and quality of
life. Field walking tests and cardiopulmonary exercise test (CPET) are two ways to measure EC. The 6-minute
walking test (6MWT) is the commonest and easiest field test. CPET has the advantage of assessing maximal
aerobic capacity. Determinants of EC include age, gender, breathlessness, and lung function. Previous research
suggests that socioeconomic status (SES), a meaningful factor in COPD, may also be associated with EC.
However, those findings have not been replicated. We aimed to determine whether SES is an independent
factor associated with EC in COPD. For this analysis, we used the National Emphysema Treatment Trial
(NETT) database. NETT was a multicenter clinical trial where severe COPD patients were randomized to lung
volume reduction surgery or medical therapy. Measures used were taken at baseline, postrehabilitation.
Patients self-reported their income and were divided in two groups whether it was less or above
US$30,000. Patients with a lower income had worse results in 6MWT (p < 0.0001). We found an
independent association between income and the 6MWT in patients with severe COPD after adjusting for
age, gender, lung function, dyspnea, and living conditions (p < 0.0007). One previous publication stated the
relationship between income and EC. Our research confirms and extends previous publications associating EC
with income by studying a large and well characterized cohort of severe COPD patients, also addressing EC by
two different methods (maximal watts and 6MWT). Our results highlight the importance of addressing social
determinants of health such as income when assessing COPD patients.
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Introduction
Exercise capacity (EC) is a critical outcome in
chronic obstructive lung disease (chronic obstructive
pulmonary disease (COPD)).1 It measures the impact
of the disease and tests the effect of specific interven-
tions.1–3 EC determines COPD prognosis due to its
relation with hospitalizations for exacerbations and
all-cause mortality.4,5 Importantly, from a patient-
centered focus, it is related to health-care utilization,
quality of life (QoL), and symptoms.3
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Field walking tests and cardiopulmonary exercise
test (CPET) are two ways to measure EC. Among
those, the 6-minute walking test (6MWT) is the com-
monest and easiest.1,2,6 CPET has the advantage of
assessing maximal aerobic capacity and contributes
better to the differential diagnosis.7 EC determinants
are many,6,8 including age, breathlessness, and lung
function.
Socioeconomic status (SES), a meaningful factor
in COPD related to QoL,9 physical activity,10 com-
pletion of pulmonary rehabilitation (PR), and all-
cause mortality,11 may also predict EC. Recent data
show that SES also influences EC, with lower income
patients having poorer results12; however, that finding
has never been replicated.
Our aim is to determine whether income is an inde-
pendent factor associated with EC in COPD, which
would raise its importance as a meaningful factor to
be assessed.
Methods
The present analysis used the National Emphysema
Treatment Trial (NETT) database.13 This multicenter
trial randomized severe COPD patients with no signif-
icant comorbidities to lung volume reduction surgery
or medical therapy, after 6–10-week PR.13,14 Smoking
cessation, biochemically validated, was required at
least 6 months before randomization. Patients were
divided in two groups whether their annual reported
income was less or above US$30,000, a limit chosen
following data of US census bureau and Pew Research
center.15,16
EC was measured by the 6MWT and maximal
watts during CPET, following the American Thoracic
Society Guidelines (ATS).6,17 Pulmonary function
tests followed ATS.18,19
Statistical analyses, associations between
income and categorical variables, were tested
between income groups using w2tests. Associations
between income level and continuous variables
were tested between groups using Wilcoxon tests.
The association between income and 6MWT as
well as income and CPET was explored using lin-
ear models adjusted for marital status, loneliness,
age, gender, FEV1% predicted, modified medical
research council scale (MMRC), smoking pack
years, and education. All analyses were tested with
5% type I error rates with no adjustments for
multiple testing. Analyses were carried out using
SAS version 9.4.
Results
In total, 1218 patients completed PR and were ana-
lyzed using baseline data. Table 1 shows population’s
characteristics and Tables 2 and 3 show the models
designed to determine the independent association
between income and EC.
The association between 6MWT and income
(Table 2) remained significant after adjusting for
meaningful confounders such as sex, age, Post BD
FEV1% predicted, MMRC, marriage, loneliness,
smoking pack years, and education beyond high
school (yes or no). We also found a significant
association between income and maximal load in
watts on CPET (Table 3) validating the 6MWT
results. In addition, our results showed individuals
with low income found themselves lonelier (Tables
1 and 2).
Discussion
We found that low income is associated with worse
results in the 6MWT after adjusting for meaningful
confounders. The latter was further validated using
another measure of EC: watts in CPET. Our findings
confirm and extend a previous report12 but in a larger
and more characterized cohort of severe COPD, using
two different EC measures.
Given the 6MWT’s prognostic significance,4–6
our findings are important because usually income
is not taken into account in COPD evaluation,
despite being a factor that is easily obtainable, and
conveys information about patients’ overall social
condition. Plausible explanations for our results
might include that financial constrains may limit
patients’ access to programs like PR, as stated by
previous publications.21–23 The fact of finding low-
income participants more lonely suggests another
social, yet critical repercussion of low income. Lone-
liness is independently related to poorer outcomes
and higher health-care utilization in COPD (article
in press).
Limitations
Given that NETT selected severe emphysema COPD
patients without significant comorbidities, our results
may limit generalizability.
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Table 1. Characteristics of all 1206 patients at baselinea.
Characteristics
Income US$30,000
(N ¼ 563)
Income US$30,000
(N ¼ 643) p Value
Medical treatment 52.0% 49.1% 0.3153
Sex, male 65.4% 57.5% 0.0054
Age, mean (SD) (years) 67.2 (5.5) 65.6 (6.6) 0.0001
Married 83.3% 48.5% <0.0001
Lonelyb 5.5% 10.1% 0.0031
Smoking pack years 65.4 (29.3) 63.6 (32.6) 0.0826
Post BD FEV1% pred, mean (SD) 26.8 (7.1) 26.6 (7.2) 0.3947
6MWD in feet, mean (SD) 1250.7 (314.8) 1171.7 (306.8) <0.0001
Maximum load (watts), mean (SD)c 41.6 (22.7) 36.8 (20.4) 0.0001
Total days in hospital, mean (SD) 3.0 (7.8) 3.3 (7.6) 0.3840
Any days in hospital, yes 31.7% 33.8% 0.4620
Total visits to ER, mean (SD) 0.6 (1.1) 0.7 (1.3) 0.5015
Any visit to ER, yes 37.5% 39.7% 0.4659
Follow-up status, deadd 39.4% 41.7% 0.4278
MRC Dyspnea Scale 0.0058
0 1.4% 1.6%
1 0.2% 0.5%
2 29.2% 22.1%
3 23.5% 19.9%
4 45.7% 55.9%
Education beyond high school 62.9% 35.1% <0.0001
N: sample; SD: standard deviation; Post BD FEV1% pred: postbronchodilator forced expiratory volume in 1 second % predicted;
ER: emergency department; MRC scale: Medical Research Council Dyspnea Scale; 6MWD: 6-minute walk distance. Every value in italics
<0.05 denotes significance (standard practice).
aBase-line measurements were obtained after rehabilitation but before randomization.
bLoneliness was measured by asking subjects “Do you feel lonely or socially isolated now or in the last 3 days?” An answer was either
“yes” or “no.”20
cMaximum load (watts) was chosen to measure exercise capacity during CPET.
dThe follow-up period was 2 years.
Table 2. Income as a determinant of 6MWT, adjusted for age, sex, Post FEV1% predicted, MMRC, loneliness, married
status, smoking pack years, and education beyond high school.
Variables DF Parameterestimates Standard error t Value Pr > |t|
Intercept 1 1607.40 95.58 16.82 <0.0001
Married 1 27.47 18.45 1.49 0.1367
Lonely or Isolateda 1 23.24 29.50 0.79 0.4310
Income < US$30,000 1 48.15 17.76 2.71 0.0068
Age 1 10.87 1.35 8.05 <0.0001
Sex, male 1 180.85 17.82 10.15 <0.0001
Post BD FEV1% pred 1 16.10 1.17 13.75 <0.0001
MMRC 1 67.59 8.61 7.85 <0.0001
Education beyond high schoolb 1 32.89 16.78 1.96 0.0502
Smoking pack years 1 0.11 0.26 0.42 0.6720
DF: degrees of freedom; Pr > |t|: t-test significance level; Post BD FEV1% pred: post bronchodilator forced expiratory volume in
1 second; MMRC: Modified medical research council scale. Every value in italics <0.05 denotes significance (standard practice).
aLoneliness and isolation was measured by asking subjects “Do you feel lonely or socially isolated now or in the last 3 days?” An answer
was either “yes” or “no.” 20
bEducation was determined by dividing patients into two groups: those who had education levels beyond high school and those who
did not.
Porta et al. 3
Conclusions
In severe COPD patients, low income is indepen-
dently associated with EC. Our results may be of
importance to fully assess patients with severe COPD
addressing social determinants of health.
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